AR097217A1 - IMMUNOGEN COMBINATION COMPOSITIONS - Google Patents

IMMUNOGEN COMBINATION COMPOSITIONS

Info

Publication number
AR097217A1
AR097217A1 ARP140102924A ARP140102924A AR097217A1 AR 097217 A1 AR097217 A1 AR 097217A1 AR P140102924 A ARP140102924 A AR P140102924A AR P140102924 A ARP140102924 A AR P140102924A AR 097217 A1 AR097217 A1 AR 097217A1
Authority
AR
Argentina
Prior art keywords
pertussis
rsv
conjugated
carrier protein
capsular saccharide
Prior art date
Application number
ARP140102924A
Other languages
Spanish (es)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR097217A1 publication Critical patent/AR097217A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Se divulgan composiciones inmunógenas de combinación que pueden provocar protección frente a infección y enfermedad tanto de VRS como de B. pertussis. Más específicamente, esta divulgación se refiere a dichas composiciones que comprenden un análogo recombinante de proteína F de VRS, junto con antígenos acelulares (Pa) o de célula entera (Pw) de B. pertussis y al uso de los mismos, en particular en el contexto de inmunización neonatal y materna. También se divulgan regímenes de vacunas, procedimientos, así como usos, y kits, de composiciones inmunógenas para proteger a lactantes frente a enfermedad provocada por VRS y B. pertussis por inmunización materna. Reivindicación 62: La composición inmunógena de combinación de la reivindicación 61, que comprende uno o más antígenos seleccionados del grupo que consiste en: toxoide diftérico (D); toxoide tetánico (T); antígeno de superficie de Hepatitis B (HBsAg); virus poliomelítico inactivado (IPV); sacárido capsular de H. influenzae tipo b (Hib) conjugado a una proteína vehículo; sacárido capsular de N. meningitidis tipo C conjugado a una proteína vehículo; sacárido capsular de N. meningitidis tipo Y conjugado a una proteína vehículo; sacárido capsular de N. meningitidis tipo A conjugado a una proteína vehículo; sacárido capsular de N. meningitidis tipo W conjugado a una proteína vehículo; y un antígeno de N. meningitidis tipo B. Reivindicación 107: Un kit que comprende una pluralidad de composiciones inmunógenas formuladas para la administración a una hembra preñada, en el que el kit comprende: (a) una primera composición inmunógena que comprende un análogo de proteína F puede inducir, provocar o reforzar una respuesta inmunitaria humoral específica para VRS; y (b) una segunda composición inmunógena que comprende al menos un antígeno de B. pertussis que puede inducir, provocar o reforzar una respuesta humoral específica para B. pertussis, en donde después de la administración a una hembra preñada, las primera y la segunda composiciones inmunógenas inducen, provocan o refuerzan al menos un subconjunto de anticuerpos específicos de VRS y al menos un subconjunto de anticuerpos específicos de B. pertussis, anticuerpos que se transfieren por medio de la placenta a un bebé en gestación de la hembra preñada, protegiendo así al lactante frente a infección o enfermedad provocada por VRS y B. pertussis.Combined immunogenic compositions that can cause protection against infection and disease of both RSV and B. pertussis are disclosed. More specifically, this disclosure relates to said compositions comprising a recombinant analog of RSV F protein, together with acellular (Pa) or whole cell (Pw) antigens of B. pertussis and their use, in particular in the context of neonatal and maternal immunization. Vaccine regimens, procedures, as well as uses, and kits of immunogenic compositions to protect infants against disease caused by RSV and B. pertussis by maternal immunization are also disclosed. Claim 62: The combination immunogenic composition of claim 61, comprising one or more antigens selected from the group consisting of: diphtheria toxoid (D); tetanus toxoid (T); Hepatitis B surface antigen (HBsAg); inactivated polyomelitic virus (IPV); capsular saccharide of H. influenzae type b (Hib) conjugated to a carrier protein; capsular saccharide of N. meningitidis type C conjugated to a carrier protein; capsular saccharide of N. meningitidis type Y conjugated to a carrier protein; capsular saccharide of N. meningitidis type A conjugated to a carrier protein; capsular saccharide of N. meningitidis type W conjugated to a carrier protein; and an N. meningitidis type B antigen. Claim 107: A kit comprising a plurality of immunogenic compositions formulated for administration to a pregnant female, wherein the kit comprises: (a) a first immunogenic composition comprising an analogue of F protein can induce, elicit or strengthen a humoral immune response specific to RSV; and (b) a second immunogenic composition comprising at least one B. pertussis antigen that can induce, elicit or reinforce a specific humoral response for B. pertussis, wherein after administration to a pregnant female, the first and second Immunogenic compositions induce, provoke or reinforce at least a subset of RSV-specific antibodies and at least a subset of B. pertussis-specific antibodies, antibodies that are transferred through the placenta to a pregnant baby of the pregnant female, thus protecting the infant against infection or disease caused by RSV and B. pertussis.

ARP140102924A 2013-08-05 2014-08-04 IMMUNOGEN COMBINATION COMPOSITIONS AR097217A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1313990.2A GB201313990D0 (en) 2013-08-05 2013-08-05 Combination immunogenic compositions

Publications (1)

Publication Number Publication Date
AR097217A1 true AR097217A1 (en) 2016-02-24

Family

ID=49224176

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102924A AR097217A1 (en) 2013-08-05 2014-08-04 IMMUNOGEN COMBINATION COMPOSITIONS

Country Status (2)

Country Link
AR (1) AR097217A1 (en)
GB (1) GB201313990D0 (en)

Also Published As

Publication number Publication date
GB201313990D0 (en) 2013-09-18

Similar Documents

Publication Publication Date Title
NI202000040A (en) COMPOSITIONS INCLUDING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATES WITH PROTEIN AND METHODS OF USE OF THESE
AR092896A1 (en) IMMUNOGENIC COMPOSITIONS
CO6430434A2 (en) NEW COMPOSITIONS OF VACCINES WITH ACCELULAR PERTUSSIS AND MANUFACTURING METHOD OF THE SAME
UY37811A (en) AN IMMUNOGENIC COMPOSITION THAT HAS IMPROVED STABILITY, POTENTIAL IMMUNOGENICITY AND REDUCED REACTOGENICITY AND PROCESS FOR THE PREPARATION OF THE SAME
AR053711A1 (en) COMBINATION OF VACCINES FOR PORCINE AND HELICOBACTER CIRCOVIRUS AND METHODS OF USE
DOP2021000127A (en) COMPOSITIONS INCLUDING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CONJUGATES WITH PROTEIN AND THEIR USE METHODS
AR061152A1 (en) RECOMBINANT VACCINE AGAINST VIRUSES OF THE BLUE LANGUAGE
TW200722101A (en) Novel composition
CO6430435A2 (en) NEW VACCINES COMBINED WITH COMPLETE CELLS OF PERTUSSIS AND MANUFACTURING METHOD OF THE SAME
BR112013017171A2 (en) stable immunogenic combination vaccine, stable combination vaccine preparation process, method of using antigenic molecules and method of administration to human subjects
CO6561819A2 (en) VECTORS FOR VACCINES AND METHOD FOR POWERING IMMUNE RESPONSES
AR080111A1 (en) IMMUNIZATION METHODS AND COMPOSITIONS
AR126891A2 (en) ROTAVIRUS SUBUNIT VACCINES, PREPARATION METHODS AND USE OF THE SAME
SG195115A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of dengue virus infection
AR088907A1 (en) VACCINE
BR112016002354A2 (en) immunogenic composition, methods to protect a baby against infection or disease and to evoke an immune response, vaccination regimen, and
AR088987A1 (en) SPECIFIC MONOCLONAL ANTIBODIES FOR THE M2-1 ANTIGEN OF THE SYNCHRIRY RESPIRATORY VIRUS (VRS), PRODUCED AND SECRETED BY CELLULAR HYBRIDOMES, USEFUL FOR THE DETECTION AND DIAGNOSIS OF THE INFECTION CAUSED BY VRS
Li et al. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost
PE20211648A1 (en) COMPOSITION OF COMBINED VACCINE INCLUDING REDUCED DOSES OF INACTIVATED POLIO VIRUS AND METHOD OF PREPARING IT
CO6731067A2 (en) Varicella zoster virus vaccines inactivated, production methods and use thereof
CA2918644A1 (en) Methods and compositions for dengue virus vaccines
AR117191A1 (en) IMMUNOGENIC COMPOSITIONS
AR097217A1 (en) IMMUNOGEN COMBINATION COMPOSITIONS
PE20200004A1 (en) NEW MULTIVALENT VACCINE COMPOSITION
RU2014147491A (en) ANTIGENS AND ANTIGENIC COMPOSITIONS

Legal Events

Date Code Title Description
FB Suspension of granting procedure